Estudio descriptivo de la esteatosis hepática y la morbilidad asociada en atención primaria. (Estudio ESTEATOAP)

  1. J.A. Cortés Rubio 1
  2. P. Costa Zamora 1
  3. R. Guerra Díaz 1
  4. M. Candela Fernández 1
  5. M. Cortés Costa 2
  1. 1 Centro de Salud Universitario Las Calesas, Madrid, España
  2. 2 Hospital Universitario Miguel Servet, Zaragoza, España
Journal:
Semergen: revista española de medicina de familia

ISSN: 1138-3593

Year of publication: 2020

Issue: 6

Pages: 400-405

Type: Article

DOI: 10.1016/J.SEMERG.2020.01.003 DIALNET GOOGLE SCHOLAR

More publications in: Semergen: revista española de medicina de familia

Sustainable development goals

Abstract

Objective To study the recorded prevalence of hepatic steatosis in Primary Care, as well as the proportion of patients diagnosed with fatty liver diseases (FLD) including simple non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) versus steatosis by other causes. In addition, the proportion of cardiometabolic morbidities associated with NAFLD liver was studied. Material and methods A descriptive observational study was carried out on a population that included all patients with a recorded diagnosis of hepatic steatosis in an urban health centre that serves a population of 25,747 over the age of 14. A sample size of 229 patients was calculated. The demographic and clinical characteristics associated with hepatic steatosis are described. Results The prevalence of steatosis was 2.17% and 1.51% for NAFLD. The mean age was 62.42 years. The study included 114 (50.2%) women and 113 (49.8%) males. NAFLD was found in 147 (64.8%), and 64 (28.2%) were steatosis due to other causes. The proportion of patients with NAFLD and high transaminases was 24.13%, and the proportion of patients with NAFLD and GGT elevation was 18.6%. A high proportion of NAFLD had been found with cardiometabolic risk factors: 93.9% overweight and obesity, 55.1% diabetes, 54.4% hypertension, 32.9% metabolic syndrome, 35.2% hypertriglyceridaemia, and HDL risk 19.6%. A significant association was found between cardiometabolic risk factors and NAFLD in diabetes, obesity, and metabolic syndrome. Discussion Prevalence was only 1.51%, perhaps because of the low importance given to this disease. There is a high proportion of NAFLD with cardiometabolic risk factors and more in the general population. If all the causes of steatosis are considered there is a significant association between obesity, diabetes mellitus, and metabolic syndrome with NAFLD. Conclusions The recorded prevalence of NAFLD is much lower than that of population studies, and a high presence of cardiometabolic factors has been found in these patients.

Bibliographic References

  • M.F. Abdelmalek, A.M. Diehl Non alcoholic fatty liver diseases and nonalcoholic steatohepatitis Harrison's Principles of Internal Medicine (19th ed), McGraw-Hill Education, New York (2015), pp. 2054-2057 View Record in ScopusGoogle Scholar
  • Caballería J. Esteatosis y esteatohepatitis no alcohólica. En: Medicina Interna Farreras-Rozman. 17.a ed. Barcelona: Elsevier; 2017. p. 330-333. Google Scholar
  • E. Sánchez, A. Quiroga, R. Veras, M. Delgado Enfermedad hepática por depósito grado no alcohólica Guía Fisterra (2017) Google Scholar
  • L.A. Adams, J.F. Lymp, J. St. Sauver, S.O. Sanderson, K.D. Lindor, A. Feldstein, P. Angulo The natural history of non alcoholic fatty liver disease a population based cohort study Gastroenterology, 1 (2005), pp. 113-121 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64:1388-1402. Google Scholar
  • R. Aller, C. Fernández-Rodríguez, O.I. Iaconoc, R. Banaresd, J. Abade, J.A. Carrión, et al. Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica Gastroentorol Hepatol (2018) Google Scholar
  • L. Caballería, P. Torán Epidemia de esteatosis hepática: un análisis desde la atención primaria Aten Primaria, 51 (2019), pp. 525-526 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • M. Samperio-Gonzales, M. Selvi-Blasco, M. Manzano-Montero, J. Méndez_Gómez, M. Gil-Prades, R. Azagra Prevalencia de la esteatosis hepática no alcohólica en población con hipertransaminasemia y grado de adecuación del diagnóstico registrado en atención primaria Aten Primaria, 48 (2016), pp. 281-287 Google Scholar
  • J.F. Cano, P. Tomas Obesidad y síndrome metabólico Atención Primaria. Problemas de salud en la consulta de Medicina de Familia (8.a ed), Elsevier, Barcelona (2019), pp. 212-234 View Record in ScopusGoogle Scholar
  • 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J. 2019. 1-78. Google Scholar
  • L. Caballeria, G. Pera, M.A. Auladell, P. Toran, L. Muñoz, D. Miranda, et al. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain Eur J Gastroenterol Hepatol, 22 (2010), pp. 24-32 View Record in ScopusGoogle Scholar
  • A. Parés, R. Tresserras, I. Nuñez, M. Cerralbo, P. Plan, F.J. Pujol, et al. Prevalencia y factores asociados a la presencia de esteatosis hepática en varones adultos aparentemente sanos Med Clin (Barc), 114 (2000), pp. 561-565 ArticleDownload PDFView Record in ScopusGoogle Scholar
Data source: Dialnet